Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

By A. Diefenbach, Eric R. Jensen, Amanda M. Jamieson, D. Raulet. Nature, 2001

1,163 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/6e3eec690aa5de8617e54c975ea821826242dfd4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Raulet
2. A. Steinle
3. I. Waldhauer
4. Zena Werb
5. Hugo Gonzalez
6. C. Hagerling
7. S. Gasser
8. W. Deng

In Oncology

1. D. Raulet
2. Hugo Gonzalez
3. A. Steinle
4. Erik Sahai
5. W. Gu
6. Lisette G. de Pillis
7. Zena Werb
8. I. Waldhauer

Citations in the corpus

• Gammadelta T cells for immune therapy of patients with lymphoid malignancies. (2003, neutral): “1 106 4 62 (3-153) 45 (0-122) 0/4 (0) 23 (18-27) 8 ( 38-54) 0/2 (0) 183 (82-426) 322 (0-1253) 3/4 (75) 2 106 3 65 (52-98) 60 (19-121) 2/3 (66) 81 ( 37-103) 93 (79-291) 2/3 (66) 186 (62-230) 124 (122-571) 3/3 (100)”
• Natural Killer Cells: Development, Maturation, and Clinical Utilization (2018, background): “Decades of research in rodents have demonstrated the importance of NK cells in tumor clearance (14, 117, 247, 248).”
• Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, background): “Besides NKG2D, NK cells have a repertoire of different stimulatory cell surface receptors, which, upon binding to their tumor-derived ligands, activate NK cells (Cerwenka et al. 2000; Diefenbach et al. 2000, 2001; Raulet 2003).”
• Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. (2014, neutral): “15, 16, and Figure 1A, top panel).”
• The role of the NKG2D immunoreceptor in immune cell activation and natural killing. (2002, positive): “(Bauer et al., 1999; Cerwenka et al., 2000; Diefenbach et al., 2000, 2001).”
• Regulation of ligands for the NKG2D activating receptor (2013, background): “In conventional CD8+ T cells, NKG2D may also provide costimulatory function (16, 17), although this is most evident for the subset of highly activated CD8+ T cells that lacks expression of CD28, the conventional costimulatory receptor for T cells (16).”
• Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding (2002, background): “Furthermore, in mice RAE-1-transduced cell lines were eliminated in vivo due to NK and CD8 T cell activity and induced tumor immunity against the parental cell line, supporting a role for NKG2D in the tumor immune surveillance (16, 17).”